發(fā)布時(shí)間：2018-07-12 08:30

  本文選題：E-cadherin + N-cadherin�。� 參考：《蘭州大學(xué)》2014年碩士論文

【摘要】：目的：研究上皮型鈣粘蛋白(E-cadherin)和神經(jīng)元型鈣粘蛋白(N-cadherin)在良性前列腺增生組織及前列腺癌組織中的表達(dá)情況,以探討E-cadherin和N-cadherin在前列腺癌發(fā)生發(fā)展過(guò)程中的作用及意義。 方法：采用免疫組織化學(xué)法(SP法)檢測(cè)51例前列腺癌組織和47例良性前列腺增生組織中E-cadherin和N-cadherin的表達(dá),根據(jù)半定量積分法判斷陽(yáng)性結(jié)果。根據(jù)前列腺癌的病理分化等級(jí)及臨床分期,采用x2檢驗(yàn)對(duì)E-cadherin、 N-cadherin與前列腺癌的關(guān)系進(jìn)行統(tǒng)計(jì)分析。采用RT-PCR方法檢測(cè)E-cadherin mRNA以及N-cadherin mRNA在前列腺增生和前列腺癌中的表達(dá),并進(jìn)行統(tǒng)計(jì)學(xué)分析。 結(jié)果：1.在良性前列腺增生組織中,E-cadherin陽(yáng)性表達(dá)率為87.23%,N-cadherin的陽(yáng)性表達(dá)率為4.26%；在前列腺癌組織中,E-cadherin陽(yáng)性表達(dá)率為31.37%, N-cadherin的陽(yáng)性表達(dá)率為86.27%。與前列腺增生組織中的表達(dá)結(jié)果相比較,E-cadherin和N-cadherin在前列腺癌中的表達(dá)具有顯著差異(P0.01)。2. E-cadherin在前列腺癌組織中的高分化組、中分化組以及低分化組的陽(yáng)性表達(dá)率分別為75.00%、46.67%以及10.71%; N-cadherin在前列腺癌組織中的高分化組、中分化組以及低分化組的陽(yáng)性表達(dá)率分別為37.5%、80.00%及96.43%。E-cadherin和N-cadherin在前列腺癌高、中、低分化組各組之間進(jìn)行兩兩比較,均有差異(P0.05)。3. E-cadherin在前列腺癌臨床分期A、B、C、D各期的陽(yáng)性表達(dá)率分別為100.00%、75.00%、36.84%及4.55%, N-cadherin在前列腺癌臨床分期A、B、C、D各期的陽(yáng)性表達(dá)率分別為50.00%、37.50%、57.89%及86.36%。4. E-cadherin mRNA和N-cadherin mRNA的表達(dá),在前列腺癌組織中的Gleason評(píng)分低分化組與前列腺增生組織相比較具有顯著性差異(P0.01); Gleason評(píng)分中分化組與前列腺增生組相比較具有統(tǒng)計(jì)學(xué)意義(P0.05)；而Gleason評(píng)分高分化組與前列腺增生組相比較無(wú)顯著性差異。 結(jié)論：1. E-cadherin與前列腺癌的惡性程度及臨床分期呈負(fù)相關(guān)。2.N-cadherin與前列腺癌的惡性程度及臨床分期呈正相關(guān)。
[Abstract]:Objective: to investigate the expression of E-cadherin and N-cadherin in benign prostatic hyperplasia (BPH) and prostate cancer, and to explore the role and significance of E-cadherin and N-cadherin in the development of prostate cancer. Methods: the expression of E-cadherin and N-cadherin in 51 cases of prostate cancer and 47 cases of benign prostatic hyperplasia were detected by immunohistochemical method (SP method). The relationship between E-cadherin, N-cadherin and prostate cancer was statistically analyzed by using x2 test according to the grade of pathological differentiation and clinical stage of prostate cancer. The expression of E-cadherin mRNA and N-cadherin mRNA in prostatic hyperplasia and prostate cancer were detected by RT-PCR. The result is 1: 1. The positive expression rate of E-cadherin was 4.26 in benign prostatic hyperplasia, 31.37 in prostate cancer and 86.27 in N-cadherin. The expression of E-cadherin and N-cadherin in prostate cancer was significantly different from that in benign prostatic hyperplasia (P0.01). The positive expression rates of E-cadherin in prostate cancer tissues were 75.00%, 46.67% and 10.71%, respectively, and the positive rates of N-cadherin in prostate cancer tissues were 75.00% and 10.71%, respectively. The positive expression rates of E-cadherin and N-cadherin in moderately differentiated group and poorly differentiated group were 37.50.000% and 96.43km. E-cadherin and N-cadherin were significantly higher than those in poorly differentiated group (P0.05). The positive expression rate of E-cadherin in clinical stage of prostate cancer was 100.000.The positive rate of N-cadherin in clinical stage of prostate cancer was 50.0057.50% and 86.360.45%, respectively. The positive expression rate of E-cadherin in clinical stage of prostate cancer was 57.89% and 86.36.4.The positive expression rate of E-cadherin in clinical stage of prostate cancer was 57.89% and 86.36.4.The positive expression rate of E-cadherin in clinical stage of prostate cancer was 57.89% and 86.36.4. The expression of E-cadherin mRNA and N-cadherin mRNA in prostate cancer was significantly higher than that in prostatic hyperplasia (P0.01), and there was significant difference in Gleason score between differentiated group and prostatic hyperplasia group (P0.05). There was no significant difference in Gleason score between high differentiation group and benign prostatic hyperplasia group. Conclusion 1. E-cadherin was negatively correlated with the malignant degree and clinical stage of prostate cancer. 2.N-cadherin was positively correlated with the malignant degree and clinical stage of prostate cancer.
【學(xué)位授予單位】：蘭州大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R737.25

【參考文獻(xiàn)】

相關(guān)期刊論文 前5條

1 趙雪儉,孔祥波,王偉華;前列腺特異性抗原集團(tuán)普查是前列腺癌早期診治的最佳途徑[J];中華男科學(xué);2003年08期

2 查佶;黃宇烽;;前列腺癌中TGF-β/Smad信號(hào)的研究進(jìn)展[J];中華男科學(xué)雜志;2009年09期

3 周建成;朱國(guó)棟;吳開杰;曾津;張棟;薛艷;陳玉樂;王新陽(yáng);賀大林;;上皮-間質(zhì)轉(zhuǎn)化在人胚胎前列腺發(fā)育中的發(fā)生及意義[J];中華男科學(xué)雜志;2011年02期

4 韓蘇軍;張思維;陳萬(wàn)青;李長(zhǎng)嶺;;中國(guó)前列腺癌發(fā)病現(xiàn)狀和流行趨勢(shì)分析[J];臨床腫瘤學(xué)雜志;2013年04期

5 張靈,計(jì)國(guó)義,李曉萌,李勝文,高洪文,甘卉,王洪亮,潘玉琢,孔祥波,桑原正明,趙雪儉;前列腺癌集團(tuán)檢診對(duì)臨床前列腺癌診斷的影響[J];中華泌尿外科雜志;2004年02期

，

本文編號(hào)：2116575